Skip to main content

Palatin Technologies (NYSE:PTN – Get Rating) and Abeona Therapeutics (NASDAQ:ABEO – Get Rating) are both small-cap medical companies, but which is the better company? We’ll compare the two companies based on earnings strength, valuation, institutional ownership, risk, profitability, dividends, and analyst recommendations.

Institutional and insider ownership

7.9% of Palatin Technologies shares are held by institutional investors. By comparison, 27.8% of Abeona Therapeutics shares are held by institutional investors. 9.9% of Palatin Technologies shares are held by insiders of the company. By comparison, 2.5% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large fund managers, and hedge funds believe a company will outperform the market over the long term.

Analyst Notes

This is a breakdown of the current ratings of Palatin Technologies and Abeona Therapeutics, as provided by

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Palatine Technologies 0 0 0 0 N / A
Abeona Therapeutic 0 1 2 0 2.67

Abeona Therapeutics has a consensus price target of $2.50, suggesting a potential upside of 1,370.59%. Given Abeona Therapeutics’ likely higher upside, analysts clearly believe Abeona Therapeutics is more favorable than Palatin Technologies.


This table compares the net margins, return on equity and return on assets of Palatin Technologies and Abeona Therapeutics.

Net margins Return on equity return on assets
Palatine Technologies -4,280.18% -95.87% -66.77%
Abeona Therapeutic N / A -96.64% -62.00%

Valuation and benefits

This table compares the revenue, earnings per share (EPS) and valuation of Palatin Technologies and Abeona Therapeutics.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Palatine Technologies $120,000.00 592.75 -$33.60 million ($0.16) -1.92
Abeona Therapeutic $3.00 million 8.33 -84.94 million dollars ($0.82) -0.21

Palatin Technologies has higher revenues, but lower revenues than Abeona Therapeutics. Palatin Technologies trades at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and risk

Palatin Technologies has a beta of 1, meaning its stock price has a similar volatility profile to the S&P 500. In comparison, Abeona Therapeutics has a beta of 1.51, meaning its stock price is 51 % more volatile than the S&P 500.


Abeona Therapeutics beats Palatin Technologies on 8 of the 13 factors compared between the two stocks.

Palatin Technologies Company Profile (Get an evaluation)

Palatin Technologies, Inc., a biopharmaceutical company, is developing receptor-specific targeted therapies for the treatment of various diseases in the United States. The Company’s lead product is Vyleesi, a melanocortin (MCr) receptor agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Additionally, the Company is engaged in the development of PL9643, a melanocortin peptide agonist active on several MCr, including MC1r and MC5r for ocular anti-inflammatory indications, such as dry eye; and melanocortin peptides for diabetic retinopathy. In addition, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic endogenous atrial natriuretic peptide mimetic of neuropeptide hormone for cardiovascular indications; and PL5028, an NPR-A and NPR binder for treating cardiovascular and fibrotic diseases, including reducing cardiac enlargement and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Abeona Therapeutics Company Profile (Get an evaluation)

Abeona Therapeutics logoAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, is focused on developing and delivering gene therapy products for serious and life-threatening rare diseases. The Company’s principal programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV-based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type B. It is also developing an ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for the treatment of childhood Batten disease; EB-201 for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach for a gene therapy program for rare blood diseases. Additionally, it is involved in the commercialization of MuGard, a mucoadhesive mouthwash for the management of mucositis, stomatitis, aphthous ulcers and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for the commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive daily news and reviews for Palatin Technologies – Enter your email address below to receive a concise daily summary of breaking news and analyst assessments for Palatin Technologies and related companies with’s free daily email newsletter.